ABOS stock icon

Acumen Pharmaceuticals
ABOS

$3.07
3.17%

Market Cap: 184M

 

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

20% more funds holding

Funds holding: 66 [Q4 2023] → 79 (+13) [Q1 2024]

19% more capital invested

Capital invested by funds: $148M [Q4 2023] → $176M (+$28M) [Q1 2024]

5.8% more ownership

Funds ownership: 66.38% [Q4 2023] → 72.18% (+5.8%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

63% less call options, than puts

Call options by funds: $1.54M | Put options by funds: $4.13M

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$15
389%
upside
Avg. target
$15
389%
upside
High target
$15
389%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
389%upside
$15
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Andrew Fein
389%upside
$15
Buy
Maintained
27 Mar 2024

Financial journalist opinion